Alzheimer's dementia (AD) is a degenerative brain disorder characterized mainly by cholinergic failure, but other neuro-transmitters are also deficient especially at late stages of the disease. Misfolded β-amyloid peptide has been identified as a causative agent, however inflammatory changes also play a pivotal role. Even though the most prominent pathology is seen in the cognitive functions, specific abnormalities of the central nervous system (CNS) are also reflected in the periphery, particularly in the immune responses of the body. The aim of this study was to characterize the dopaminergic and serotonergic systems in AD, which are also markedly disrupted along with the hallmark acetyl-choline dysfunction. Peripheral blood mono-nuclear c...
Clinical and pathological evidence points to an involvement of dopamine in Alzheimer's disease (AD)....
Objectives: Among several other factors, the neuro-toxic β-amyloid peptide (βAP)-induced inflammator...
The overall goal of all therapeutic interventions in Alzheimer's disease (AD) is to: (a) optimize th...
Alzheimer's dementia (AD) is a degenerative brain disorder characterized mainly by cholinergic failu...
AbstractAlzheimer's dementia (AD) is a degenerative brain disorder characterized mainly by cholinerg...
Alzheimer’s disease (AD) represents the most common cause of dementia in the elderly. AD is a neurod...
Behavioural and psychological disorders are frequent not only in frontotemporal dementia (FTD), but ...
Alzheimer's disease (AD) is a chronic progressive disorder characterized by dementia, but often feat...
Serotonin or 5-hydroxytryptamine (5-HT) is primarily involved in the regulation of learning and memo...
Depression and aggression in Alzheimer's disease (AD) are 2 of the most severe and prominent neurops...
Muscarinic M2-M5 muscarinic cholinergic receptors were investigated in peripheral blood lymphocytes ...
Although primarily a neurological complaint, systemic inflammation is present in Alzheimer's Disease...
Alzheimer’s disease (AD), a common fatal neurodegenerative disorder is manifested by core features o...
Introduction. Peripheral blood lymphocytes (PBL) express neurotransmitter and neuropeptide receptors...
Clinical and pathological evidence points to an involvement of dopamine in Alzheimer's disease (AD)....
Clinical and pathological evidence points to an involvement of dopamine in Alzheimer's disease (AD)....
Objectives: Among several other factors, the neuro-toxic β-amyloid peptide (βAP)-induced inflammator...
The overall goal of all therapeutic interventions in Alzheimer's disease (AD) is to: (a) optimize th...
Alzheimer's dementia (AD) is a degenerative brain disorder characterized mainly by cholinergic failu...
AbstractAlzheimer's dementia (AD) is a degenerative brain disorder characterized mainly by cholinerg...
Alzheimer’s disease (AD) represents the most common cause of dementia in the elderly. AD is a neurod...
Behavioural and psychological disorders are frequent not only in frontotemporal dementia (FTD), but ...
Alzheimer's disease (AD) is a chronic progressive disorder characterized by dementia, but often feat...
Serotonin or 5-hydroxytryptamine (5-HT) is primarily involved in the regulation of learning and memo...
Depression and aggression in Alzheimer's disease (AD) are 2 of the most severe and prominent neurops...
Muscarinic M2-M5 muscarinic cholinergic receptors were investigated in peripheral blood lymphocytes ...
Although primarily a neurological complaint, systemic inflammation is present in Alzheimer's Disease...
Alzheimer’s disease (AD), a common fatal neurodegenerative disorder is manifested by core features o...
Introduction. Peripheral blood lymphocytes (PBL) express neurotransmitter and neuropeptide receptors...
Clinical and pathological evidence points to an involvement of dopamine in Alzheimer's disease (AD)....
Clinical and pathological evidence points to an involvement of dopamine in Alzheimer's disease (AD)....
Objectives: Among several other factors, the neuro-toxic β-amyloid peptide (βAP)-induced inflammator...
The overall goal of all therapeutic interventions in Alzheimer's disease (AD) is to: (a) optimize th...